Core Viewpoint - The company has approved a strategic plan for 2026-2030 to adapt to macroeconomic changes and technological transformations, aiming to strengthen its market position and drive growth [1][2]. Group 1: Board Meeting Details - The board meeting was held on October 15, 2025, in Shanghai, with all 9 directors present, including participation via communication methods [1]. - The meeting was chaired by Chairman Deng Haibin, with all senior executives in attendance [1]. Group 2: Strategic Planning - The strategic plan focuses on two main growth curves: enhancing the existing pharmaceutical business through management improvements and acquisitions, and exploring new opportunities for innovation and development [2]. - The property management sector will continue to operate steadily, contributing stable cash profits to support both growth curves [2]. - The company aims to achieve high-quality development and continuous value growth through a dual strategy of "industrial operation + investment and mergers" [2].

Group 1 - The board of directors of Shanghai Haixin Group Co., Ltd. held its 13th meeting of the 11th session on October 15, 2025, in accordance with relevant laws and regulations [2][3] - The meeting was attended by all 9 directors, with some participating via communication methods [2] - The board unanimously approved the strategic plan for 2026-2030, focusing on strengthening the company's core business and exploring new growth opportunities through mergers and acquisitions [3] Group 2 - The strategic plan aims to adapt to macroeconomic changes and industry transformations while enhancing the company's operational capabilities [3] - The company will pursue a dual strategy of "industrial operation + investment and mergers" to drive innovation and high-quality development [3] - The property management sector is expected to continue providing stable cash flow to support the company's growth initiatives [3]